A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease

I7S-EW-HBEC -

The purpose of part B of this study will evaluate how safe LY3154207 is and the effect it has on the body.

Trial Summary

Age Range
≥20 years
Conditions the trial is for
Parkinson's Disease
What the trial is testing?
LY3154207
Could I receive a Placebo?
Yes
Enrollment Goal
80
Trial Dates
Sep 30, 2015 - Mar 3, 2017
How long will I be in the trial?
Your participation could last up to 49 weeks including a 17 day stay in the clinical research unit (CRU) and follow-up.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.